Reconciling PM10 analyses by different sampling methods for Iron King Mine tailings dust

Arbuscular Mycorrhizal Fungi Drive Organo-Mineral Association in Iron Ore Tailings: Unravelling Microstructure at the Submicron Scale by Synchrotron-Based FTIR and STXM-NEXAFS

Arbuscular mycorrhizal (AM) fungi play an important role in organic matter (OM) stabilization in Fe ore tailings for eco-engineered soil formation. However, little has been understood about the AM fungi-derived organic signature and organo-mineral interactions in situ at the submicron scale. In this study, a compartmentalized cultivation system was used to investigate the role of AM fungi in OM formation and stabilization in tailings. Particularly, microspectroscopic analyses including synchrotron-based transmission Fourier transform infrared (FTIR) and scanning transmission X-ray microspectroscopy combined with near-edge X-ray absorption fine structure spectroscopy (STXM-NEXAFS) were employed to characterize the chemical signatures at the AM fungal-mineral and mineral-OM interfaces at the submicron scale. The results indicated that AM fungal mycelia developed well in the tailings and entangled mineral particles for aggregation. AM fungal colonization enhanced N-rich OM stabilization through organo-mineral association. Bulk spectroscopic analysis together with FTIR mapping revealed that fungi-derived lipids, proteins, and carbohydrates were associated with Fe/Si minerals. Furthermore, STXM-NEXAFS analysis revealed that AM fungi-derived aromatic, aliphatic, and carboxylic/amide compounds were heterogeneously distributed and trapped by Fe(II)/Fe(III)-bearing minerals originating from biotite-like minerals weathering. These findings imply that AM fungi can stimulate mineral weathering and provide organic substances to associate with minerals, contributing to OM stabilization and aggregate formation as key processes for eco-engineered soil formation in tailings.

Bioaccessibilities of metal(loid)s and organic contaminants in particulates measured in simulated human lung fluids: A critical review

Particle-bound pollutants can pose a health risk to humans. Inhalation exposure evaluated by total contaminant concentrations significantly overestimates the potential risk. To assess the risk more accurately, bioavailability, which is the fraction that enters into the systemic circulation, should be considered. Researchers have replaced bioavailability by bioaccessibility due to the rapid and cost-efficient measurement for the latter, especially for assessment by oral ingestion. However, contaminants in particulates have different behavior when inhaled than when orally ingested. Some of the contaminants are exhaled along with exhalation, and others are deposited in the lung with the particulates. In addition, a fraction of the contaminants is released into the lung fluid and absorbed by the lung, and another fraction enters systemic circulation under the action of cell phagocytosis on particulates. Even if the release fraction, i.e., release bioaccessibility, is considered, the measurement faces many challenges. The present study highlights the factors influencing release bioaccessibility and the incorporation of inhalation bioaccessibility into the risk assessment of inhaled contaminants. Currently, there are three types of extraction techniques for simulated human lung fluids, including simple chemical solutions, sequential extraction techniques, and physiologically based techniques. The last technique generally uses three kinds of solution: Gamble's solution, Hatch's solution, and artificial lysosomal fluid, which are the most widely used physiologically based simulated human lung fluids. External factors such as simulated lung fluid composition, pH, extraction time, and sorption sinks can affect release bioaccessibility, whereas particle size and contaminant properties are important internal factors. Overall, release bioaccessibility is less used than bioaccessibility considering the deposition fraction when assessing the risk of contaminants in inhaled particulates. The release bioaccessibility measurement poses two main challenges: developing a unified, accurate, stable, simple, and systematic biologically based method, and validating the method through in-vivo assays.